高级检索
当前位置: 首页 > 详情页

LncRNA-AC02278.4 Is a Novel Prognostic Biomarker That Promotes Tumor Growth and Metastasis in Lung Adenocarcinoma

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Kunming Med Univ, Dept Neurosurg, Affiliated Hosp 2, Kunming, Peoples R China [2]Puer Peoples Hosp, Hematol & Rheumatol Dept, Pu'er, Peoples R China [3]First Peoples Hosp Yunnan Prov, Dept Cardiovasc Surg, Kunming, Peoples R China [4]Yunnan Univ, Inst Ecol Res & Pollut Control Plateau Lakes, Sch Ecol & Environm Sci, Kunming, Peoples R China [5]Kunming Med Univ, Dept Resp Med, Hosp 2, Kunming, Peoples R China [6]Univ Chinese Acad Sci, Kunming Coll Life Sci, Beijing, Peoples R China
出处:
ISSN:

关键词: lncRNA-AC02278 4 lung adenocarcinoma prognosis biomarker cell proliferation cell migration

摘要:
LncRNA-AC02278.4 (ENSG00000248538) is a long non-coding RNA (lncRNA) found to be highly expressed in multiple human cancers including lung adenocarcinoma (LUAD). However, the underlying biological function and potential mechanisms of AC02278.4 driving the progression of LUAD remain unclear. In this study, we investigated the role of AC02278.4 in LUAD and found that AC02278.4 expression was significantly increased in datasets extracted from The Cancer Genome Atlas. Increased expression of lncRNA-AC02278.4 was correlated with advanced clinical parameters. Receiver operating characteristic (ROC) curve analysis revealed the significant diagnostic ability of AC02278.4 [area under the ROC curve (AUC) = 0.882]. In addition, gene set enrichment analysis (GSEA) enrichment showed that AC02278.4 expression was correlated with immune response-related signaling pathways. Finally, we determined that AC02278.4 regulated cell proliferation and migration of LUAD in vitro. Our clinical sample results also confirmed that AC02278.4 was highly expressed in LUAD and correlated with adverse clinical outcomes. In conclusion, our data demonstrated that AC02278.4 was correlated with progression and immune infiltration and could serve as a prognostic biomarker for LUAD.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
最新[2023]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
JCR分区:
出版当年[2021]版:
Q2 ONCOLOGY
最新[2023]版:
Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Kunming Med Univ, Dept Neurosurg, Affiliated Hosp 2, Kunming, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [5]Kunming Med Univ, Dept Resp Med, Hosp 2, Kunming, Peoples R China [6]Univ Chinese Acad Sci, Kunming Coll Life Sci, Beijing, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:82478 今日访问量:0 总访问量:681 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号